Cubist Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUBIST, and when can generic versions of CUBIST drugs launch?
CUBIST has seven approved drugs.
There are thirty US patents protecting CUBIST drugs.
There are three hundred and forty-one patent family members on CUBIST drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.
Summary for Cubist
| International Patents: | 341 |
| US Patents: | 30 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 7 |
| PTAB Cases with Cubist as patent owner: | See PTAB cases with Cubist as patent owner |
Drugs and US Patents for Cubist
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | DISCN | Yes | No | 9,138,456 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | 8,426,389 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | 9,988,406 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | 10,420,841 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | 8,968,753 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cubist
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 6,469,030 | ⤷ Try a Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 6,468,967 | ⤷ Try a Trial |
| Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 5,250,542 | ⤷ Try a Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 8,058,238 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 12 mg | ➤ Subscribe | 2017-06-16 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
| ➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
International Patents for Cubist Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Tunisia | 2015000411 | ⤷ Try a Trial |
| Japan | 6151257 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2008091554 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2005112990 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2010091131 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cubist Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1699784 | CA 2015 00048 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325 |
| 1556389 | 2015/074 | Ireland | ⤷ Try a Trial | PRODUCT NAME: CEFTOLOZANE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR A SULFURIC ACID SALT; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918 |
| 1539977 | 122015000026 | Germany | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICIN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205 |
| 1699784 | 243 50021-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLIDFOSFAT; REGISTRATION NO/DATE: EU/1/15/991/001 - EU/1/15/991/003 20150325 |
| 1539977 | 2015/019 | Ireland | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205; FIRST REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
